Leap Therapeutics, Inc. Banner Image

Leap Therapeutics, Inc.

  • Ticker LPTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Leap Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Cambridge, Massachusetts
Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a collaborationMore with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
4.7 / 5.0 (130)

Leap Therapeutics, Inc. reports have an aggregate usefulness score of 4.7 based on 130 reviews.

Leap Therapeutics, Inc.

Most Recent Annual Report

Leap Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Leap Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!